Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 68fludarabine phosphate 59Peripheral Blood Stem Cell Transplantation 51Cyclophosphamide 48Busulfan 46Tacrolimus 36Mycophenolic Acid 35Etoposide 33Cyclosporine 32Methotrexate 29Whole-Body Irradiation 28Antilymphocyte Serum 28Filgrastim 27Flow Cytometry 22Mitoxantrone 19Radiotherapy 18Daunorubicin 18Melphalan 16Idarubicin 16sargramostim 13Gene Expression Profiling 12Clofarabine 12Polymerase Chain Reaction 11Methylprednisolone 11Decitabine 10Cord Blood Stem Cell Transplantation 10merphos 9Transplantation 9Immunologic Techniques 9Granulocyte Colony-Stimulating Factor 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Congenital Abnormalities × Amsacrine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡